DYRK1B and ovarian carcinoma: Although a few studies show that Mirk/Dyrk1B mediates ovarian cancer cell survival, in particular for quiescent tumor cells, and depleting Mirk kinase increase cisplatin toxicity associated with higher level of reactive oxygen species (ROS) in ovarian cancer cells (23,26), insufficient data regarding the effect of Mirk/Dyrk1B on human ovarian cancer cells are available, and the mechanisms involved remain unclear.